<DOC>
	<DOC>NCT00384826</DOC>
	<brief_summary>To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.</brief_summary>
	<brief_title>Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>CBA histologically proven (or cytologically with pneumonic presentation) PS &lt; 3 signed and written informed consent visible tumoral lesion in bronchial fibroscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Adenocarcinoma, Bronchiolo-Alveolar</keyword>
</DOC>